Impact of Prolonged use of COVID-19 Drugs on the Human Neurological System using Insilco Drug-gene Interaction

Abstract

Coronavirus disease (COVID-19) was an infectious illness brought on by the SARS-CoV-2 virus. The first known SARS-CoV-2 infection was detected in the Wuhan District of China. The diagnostic and therapeutic management of COVID-19 requires an immediate response, as an alternative, quicker in-silico techniques can be used, which can serve as a filter before wet lab validation. A pharmaceutical drug, also known as a medication or medicine, is a chemical substance that is used to treat, cure, prevent, or diagnose a disease or to promote overall health. When a particular class of drugs is used to treat a diseased gene, it can also affect the various healthy non-diseased genes in the body, resulting in altered gene expression and gene function. The adverse effects of medications prescribed to COVID-19 patients form the basis of this study, which genes were being targeted, and what disorders or traits were caused as a result of this activity. COVID-19 is said to cause inflammation of the brain's tissues; inflammation of brain tissue is also a risk factor for Alzheimer's disease. The SARS-CoV-2 infection activates the inflammasome pathway, which is seen in patients with neurodegenerative diseases such as Alzheimer's and Parkinson's. SARS-CoV-2 can enter the brain via the olfactory system or can be transferred through infected immune cells. The virus could enter the body by infecting endothelial cells of the brain. The presence of ACE2 receptors, SARS-CoV-2 receptors, interleukin (IL)-6, IL-1b, tumour necrosis factor (TNF), and IL-17 disrupts the Blood Brain Barrier, allowing the virus to enter the brain.